Volume 27, Number 3—March 2021
CME ACTIVITY - Research
Effectiveness of Preventive Therapy for Persons Exposed at Home to Drug-Resistant Tuberculosis, Karachi, Pakistan
Table 1
Regimen | Drug 1, dose | Drug 2, dose |
---|---|---|
Levofloxacin/ethambutol |
Levofloxacin, <5 y: 15–20 mg/kg, >5 y: 7.5–10 mg/kg; max. dose 1,000 mg/d |
Ethambutol, 15–25 mg/kg; max. dose 2,000 mg/kg |
Levofloxacin/ethionamide |
Levofloxacin, <5 y: 15–20 mg/kg, >5 y: 7.5–10 mg/kg; max. dose 1,000 mg/d |
Ethionamide, 15–20 mg/kg; max. dose 750 mg/kg |
Moxifloxacin/ethambutol |
Moxifloxacin, 7.5–10 mg/kg; max. dose 400 mg/d |
Ethambutol, 15–25 mg/kg; max. dose 2,000 mg/kg |
Moxifloxacin/ethionamide |
Moxifloxacin, 7.5–10 mg/kg; max. dose 400 mg/d |
Ethionamide, 15–20 mg/kg; max. dose 750 mg/kg |
*Max., maximum. |
1These authors contributed equally to this article.
Page created: January 11, 2021
Page updated: February 19, 2021
Page reviewed: February 19, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.